Cytek Biosciences Inc. Releases Investor Presentation Highlighting Leading Cell Analysis Tools and 2025 Outlook

Reuters09-10

Cytek Biosciences Inc. Releases Investor Presentation Highlighting Leading Cell Analysis Tools and 2025 Outlook

Cytek Biosciences Inc. presented its September 2025 Investor Presentation, highlighting its achievements and financial performance. The company reported a strong financial profile with a total trailing twelve months $(TTM)$ revenue of $196.0 million, which includes a 16% year-over-year increase in recurring revenue. Cytek detailed its product lineup, including the launch of the Evo Analyzer in 2025 and the ESP Detection Option in 2024. The company has placed 3,295 units globally, serving approximately 2,000 customers across over 70 countries. Moreover, Cytek has been recognized with the 2024 Biotech Breakthrough Award as the Overall Biotech Company of the Year. The presentation also outlined the company's revenue guidance for 2025, projecting between $196 million and $205 million. Cytek maintains a cash and marketable securities position of $262 million. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytek Biosciences Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2566418726?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-10 06:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566418726","market":"nz","top_or_hot":-1,"title":"Cytek Biosciences Inc. Releases Investor Presentation Highlighting Leading Cell Analysis Tools and 2025 Outlook","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cytek Biosciences Inc. Releases Investor Presentation Highlighting Leading Cell Analysis Tools and 2025 Outlook\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cytek Biosciences Inc. presented its September 2025 Investor Presentation, highlighting its achievements and financial performance. The company reported a strong financial profile with a total trailing twelve months <a href=\"https://laohu8.com/S/TTM\">$(TTM)$</a> revenue of $196.0 million, which includes a 16% year-over-year increase in recurring revenue. Cytek detailed its product lineup, including the launch of the Evo Analyzer in 2025 and the ESP Detection Option in 2024. The company has placed 3,295 units globally, serving approximately 2,000 customers across over 70 countries. Moreover, Cytek has been recognized with the 2024 Biotech Breakthrough Award as the Overall Biotech Company of the Year. The presentation also outlined the company's revenue guidance for 2025, projecting between $196 million and $205 million. Cytek maintains a cash and marketable securities position of $262 million. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytek Biosciences Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cytek Biosciences Inc. Releases Investor Presentation Highlighting Leading Cell Analysis Tools and 2025 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytek Biosciences Inc. Releases Investor Presentation Highlighting Leading Cell Analysis Tools and 2025 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-10 06:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cytek Biosciences Inc. Releases Investor Presentation Highlighting Leading Cell Analysis Tools and 2025 Outlook\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cytek Biosciences Inc. presented its September 2025 Investor Presentation, highlighting its achievements and financial performance. The company reported a strong financial profile with a total trailing twelve months <a href=\"https://laohu8.com/S/TTM\">$(TTM)$</a> revenue of $196.0 million, which includes a 16% year-over-year increase in recurring revenue. Cytek detailed its product lineup, including the launch of the Evo Analyzer in 2025 and the ESP Detection Option in 2024. The company has placed 3,295 units globally, serving approximately 2,000 customers across over 70 countries. Moreover, Cytek has been recognized with the 2024 Biotech Breakthrough Award as the Overall Biotech Company of the Year. The presentation also outlined the company's revenue guidance for 2025, projecting between $196 million and $205 million. Cytek maintains a cash and marketable securities position of $262 million. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytek Biosciences Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTKB","symbol_name":"Cytek BioSciences","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nNDL8Mttsp:1","article_id":"2566418726","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566418726","pubTimestamp":1757458787,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cytek Biosciences Inc. presented its September 2025 Investor Presentation, highlighting its achievements and financial performance. The company reported a strong financial profile with a total trailing twelve months  revenue of $196.0 million, which includes a 16% year-over-year increase in recurring revenue. Cytek detailed its product lineup, including the launch of the Evo Analyzer in 2025 and the ESP Detection Option in 2024. The company has placed 3,295 units globally, serving approximately 2,000 customers across over 70 countries. Moreover, Cytek has been recognized with the 2024 Biotech Breakthrough Award as the Overall Biotech Company of the Year. The presentation also outlined the company's revenue guidance for 2025, projecting between $196 million and $205 million. Cytek maintains a cash and marketable securities position of $262 million. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CTKB":"Cytek BioSciences","BK4539":"次新股","BK4121":"生命科学工具和服务"},"translate_title":"Cytek Biosciences Inc.发布投资者演讲，重点介绍领先的细胞分析工具和2025年展望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTKB":0.9},"content_text":"Cytek Biosciences Inc. Releases Investor Presentation Highlighting Leading Cell Analysis Tools and 2025 Outlook\n    \n\n        Cytek Biosciences Inc. presented its September 2025 Investor Presentation, highlighting its achievements and financial performance. The company reported a strong financial profile with a total trailing twelve months $(TTM)$ revenue of $196.0 million, which includes a 16% year-over-year increase in recurring revenue. Cytek detailed its product lineup, including the launch of the Evo Analyzer in 2025 and the ESP Detection Option in 2024. The company has placed 3,295 units globally, serving approximately 2,000 customers across over 70 countries. Moreover, Cytek has been recognized with the 2024 Biotech Breakthrough Award as the Overall Biotech Company of the Year. The presentation also outlined the company's revenue guidance for 2025, projecting between $196 million and $205 million. Cytek maintains a cash and marketable securities position of $262 million. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytek Biosciences Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2566418726","isCrawlerRequest":true}